Atrium Therapeutics Inc.
RNA | NASDAQ
$8.47
+$0.20 (+2.42%)
Nov 2, 2026, 11:24 AM ET · Market open
TTM Period Ending | Q2 2026 Jun 30, 2026 | Q1 2026 Mar 31, 2026 | Q4 2025 Dec 31, 2025 |
|---|---|---|---|
Net Income | -65.96M | -45.77M | -29.14M |
Depreciation & Amortization | 616K | 273K | 122K |
Stock-Based Compensation | 3.55M | 3.55M | 3.55M |
Other Working Capital | 4.64M | -7.17M | 1.95M |
Other Non-Cash Items | 14.87M | 13.47M | 416K |
Deferred Income Tax | 34K | 34K | 34K |
Change in Working Capital | -7.44M | -21.96M | 5.76M |
Operating Cash Flow | -54.32M | -50.4M | -19.25M |
Capital Expenditures | -3.01M | -2.98M | -879K |
Cash Acquisitions | n/a | n/a | n/a |
Purchase of Investments | -191.55M | n/a | n/a |
Sales Maturities Of Investments | n/a | n/a | n/a |
Other Investing Acitivies | n/a | n/a | n/a |
Investing Cash Flow | -194.56M | -2.98M | -879K |
Debt Repayment | n/a | n/a | n/a |
Common Stock Repurchased | n/a | n/a | n/a |
Dividend Paid | n/a | n/a | n/a |
Other Financial Acitivies | 321.64M | 321.64M | 20.13M |
Financial Cash Flow | 321.64M | 321.64M | 20.13M |
Net Cash Flow | 72.65M | 267.85M | n/a |
Free Cash Flow | -57.33M | -53.37M | -20.13M |
Adj. Free Cash Flow | -60.89M | -56.92M | -23.68M |
Maintenance CapEx | n/a | n/a | n/a |
Growth CapEx | n/a | n/a | n/a |
Owner Earnings | n/a | n/a | n/a |
Add to Watchlist
Select watchlists to add or remove RNA